In just nine months China has issued a national BCI blueprint, overtaken the United States in BCI patent filings, funnelled hundreds of millions into startups, and has just granted the world’s first commercial implant approval.

Here are the facts. In the past 72 hours alone:

• China’s NMPA cleared Neuracle’s implantable BCI for commercial sale — the first regulator on Earth to do so.
• StairMed Technology, a Shanghai startup, closed a $72.5 million round led by Alibaba, with Tencent on the cap table.

In the past two weeks:

• Gestala raised $21.6 million for an ultrasound-based BCI, 2.5 times oversubscribed.
• NeuroXess broke ground on China’s first BCI production facility.

No other country on Earth is moving this fast. And no other country has a plan this deliberate.

China’s Blueprint

In July 2025, the Ministry of Science and Technology, together with six other central agencies — including the NDRC, the National Health Commission, and the Chinese Academy of Sciences — released a document titled Implementation Opinions on Promoting Innovation and Development of the Brain-Computer Interface Industry. It is the most explicit state-level BCI strategy any government has published anywhere.

The blueprint’s targets are concrete and highly ambitious. By 2027: breakthroughs in core technologies, internationally competitive electrode, chip, and full-system products, and the emergence of three to five BCI unicorn companies from Beijing alone. By 2030: a mature industry ecosystem anchored by two to three globally dominant firms, positioning China at the front of the global BCI pack.

Sichuan province has committed to performing 3,000 invasive BCI surgeries annually by the end of that timeline, serving over 100,000 patients with neurological and psychiatric disorders each year.

China has executed precisely this playbook before — in solar panels, in electric vehicles, in 5G, and even in building cities (read my article on the Shenzhen Strategy here: https://x.com/VelcoDar/status/2001276061842075776?s=20) — and the pattern is unmistakable: top-down industrial policy, coordinated procurement, insurance integration, and aggressive capital injections.

By 2024, China had registered 2,276 BCI invention and utility model patents, with corporate filings accounting for more than half the global total. The domestic BCI market had reached $446 million and was growing at nearly 19 per cent year on year, projected to hit $777 million by 2027.

The Companies

Neuracle Medical Technology just received full NMPA market authorisation for a coin-sized wireless implant that sits on the brain’s surface without penetrating cortical tissue, restoring hand function in spinal cord injury patients. Any qualified hospital in China can now buy and implant the device. (Neuralink, by comparison, still operates under an FDA investigational device exemption limited to twenty-one patients). The company has already begun its IPO tutoring process for a Star Market listing.

StairMed Technology, barely four years old, brought Alibaba and Tencent into the BCI sector for the first time with a single $72.5 million strategic round. Its wireless implant completed its first human implantation in early 2025. The company plans multicenter registration trials targeting forty patients before December.

Gestala, backed by Shanda Interactive billionaire Tianqiao Chen, is pursuing phased-array ultrasound rather than electrodes — a non-invasive alternative that sidesteps surgery entirely. Its $21.6 million round was 2.5 times oversubscribed. The first prototype is due before year-end.

NeuroXess, which completed China’s first prospective invasive BCI human trial in 2025, is building a 14,300-square-metre production facility in Jiangxi designed to produce tens of thousands of units.

Every one of these companies has regulatory fast-track status, institutional capital, and clinical enrolment targets measured in dozens of patients per quarter. Policy and product are moving in lockstep.

The Regulatory Weapon — how can China move so fast?

The NMPA’s “green channel” — a fast-track pathway for breakthrough medical devices — has become a competitive weapon. Neuracle used it. StairMed has it. The speed at which these companies are moving from first-in-human to registration trials would be difficult to replicate under the FDA’s current framework, where Neuralink’s PRIME study still operates under carefully gated expansion protocols.

But it is not all about approval speed. Financial infrastructure and reimbursement matters more. The National Healthcare Security Administration designated BCI procedures as independently billable medical services in 2025. Hospitals can charge for them and patients can be reimbursed — removing the adoption bottleneck that has stalled medical devices in other markets for years.

Shanghai launched the country’s first BCI industry cluster in June 2025. Guangdong is home to eighty BCI companies.

Meanwhile, in the West

While China builds, the West regulates — slowly, and in fragments.

The United States has no federal neural data law. California, Colorado, and Montana have each passed their own protections; Connecticut’s takes effect in July. But there is no federal floor. The EU AI Act classifies BCIs as high-risk systems but does not name brain data explicitly — it falls under GDPR by inference. Chile enshrined neurorights in its constitution in 2021, but Chile is not building a BCI industry.

The approach is fragmented: Chile protects the individual. The EU regulates the technology. The US lets the market decide. China builds the industry.

Two Wings and a Military Edge

The China Brain Project, a multi-billion-yuan initiative approved in 2017, is structured as “one body and two wings.” The core body is basic research on the neural mechanisms of cognition. The two wings are treatments for major brain disorders and brain-inspired artificial intelligence. It is this second wing — AI systems modelled on human cognition — where neuroscience and artificial intelligence converge most powerfully.

The Haihe Laboratory at Tianjin University, one of China’s premier BCI research hubs, signed a strategic cooperation agreement with the Academy of Military Sciences in 2024. CEC Brain, a co-founder of that lab, has developed BCI-powered simulation systems for the People’s Liberation Army. Senior government leaders have visited the facility and urged further development to strengthen China’s technological self-reliance.

What this means for the global BCI Industry

The global BCI market is projected to grow from $3.3 billion to nearly $14 billion by 2035. China intends to own a commanding share, and as of this week it has something no other country does: a commercially approved implantable brain-computer interface on the market.

The West still has advantages — research depth, startup density, first-mover clinical experience. Neuralink has implanted twenty-one patients. Synchron has a working endovascular device. Science Corp just raised $230 million. But all of that is happening inside a system that moves cautiously by design.

China has decided that speed and rigour are not mutually exclusive — and has built the regulatory infrastructure to prove it. Regulation concurrent with innovation, not postpartum.

China is already executing aggressively. The rest of the world needs to catch up — and fast.